BMC Primary Care

Table 3 Factors associated with weight loss after dapagliflozin use

From: Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care

		weight loss of ≥3% (N = 122)	p-value
Sex	Male	71 (62.8%)	0.55
Sex	Female	51 (58.6%)	0.55
BMI	Q1	29 (58.0%)	0.71
	Q2	28 (56.0%)
	Q3	32 (65.3%)
	Q4	33 (64.7%)
Alcohol consumption	Heavy drinker^a (−)	79 (58.5%)	0.30
Alcohol consumption	Heavy drinker^a (+)	43 (66.2%)	0.30
Smoking status	Non-smoker	98 (62.0%)	0.56
Smoking status	Current smoker	24 (57.1%)	0.56
Regular exercise^b	No	74 (55.6%)	0.03
Regular exercise^b	Yes	48 (71.6%)	0.03
Hypertension	No	30 (61.2%)	0.97
Hypertension	Yes	92 (60.9%)	0.97
Dyslipidemia	No	12 (70.6%)	0.40
Dyslipidemia	Yes	110 (60.1%)	0.40
CVD	No	117 (60.6%)	0.57
CVD	Yes	5 (71.4%)	0.57
Metformin	No	23 (53.5%)	0.25
Metformin	Yes	99 (63.1%)	0.25
Sulfonylurea	No	79 (65.8%)	0.09
Sulfonylurea	Yes	43 (53.8%)	0.09
Renal function	eGFR < 60 mL/min/1.73 m²	1 (16.7%)	0.02
Renal function	eGFR ≥60 mL/min/1.73 m²	121 (62.4%)	0.02

Data are presented as number (percent)
^aHeavy drinker was defined as men who consumed ≥2 drinks per day or women who consumed ≥1 drink per day
^bRegular exercise was defined as exercising three or more times per week
Abbreviations: BMI Body mass index, HbA1c Glycated hemoglobin, GFR Glomerular filtration rate, CVD Cardiovascular disease, DM Diabetes mellitus

Back to article page

ISSN: 2731-4553

Contact us

General enquiries: journalsubmissions@springernature.com